ARS Pharmaceuticals, Inc. SPRY Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $41.32M-18.7% | $50.82M-28.4% | $70.97M-66.3% | $210.52M+250% | ||
| $203.67M-22.6% | $263.21M+67.2% | $157.39M+146% | $63.86M— | ||
| $25.35M+210% | $8.18M— | $0— | —— | ||
| $23.05M+334% | $5.31M— | $0— | —— | ||
| $284.9M-14.8% | $334.3M+44.3% | $231.73M-16.6% | $277.7M+357% | ||
| $2.47M+131% | $1.07M+85.7% | $574K+74.5% | $329K+357% | ||
| $14.45M+96.1% | $7.37M— | $0— | —— | ||
| $327.65M-6.7% | $351.15M+50.6% | $233.19M-17.1% | $281.44M+358% | ||
| $37.95M+66.1% | $22.84M+960% | $2.15M-56.3% | $4.93M+137% | ||
| $609K+9.3% | $557K— | $0-100% | $283K-80.6% | ||
| $39.15M+67.0% | $23.44M+880% | $2.39M-56.1% | $5.44M-33.5% | ||
| $96.37M— | $0— | —— | $0-100% | ||
| $213.39M+126% | $94.36M+3,786% | $2.43M-71.6% | $8.55M-48.7% | ||
| $10K0.0% | $10K0.0% | $10K+11.1% | $9K+200% | ||
| -$294.6M-139% | -$123.31M+6.1% | -$131.3M-70.7% | -$76.94M-82.1% | ||
| $114.26M-55.5% | $256.8M+11.3% | $230.76M-15.4% | $272.89M+973% | ||
| $327.65M-6.7% | $351.15M+50.6% | $233.19M-17.1% | $281.44M+358% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are ARS Pharmaceuticals, Inc.'s total assets?
- ARS Pharmaceuticals, Inc. (SPRY) holds $287.6M in total assets, down 12.1% year over year.
- How much debt does ARS Pharmaceuticals, Inc. have?
- ARS Pharmaceuticals, Inc. carries $96.5M in total debt against $61.3M of shareholders' equity, a debt-to-equity ratio of 1.57.
- How much cash does ARS Pharmaceuticals, Inc. have?
- ARS Pharmaceuticals, Inc. holds $24.3M in cash and equivalents.
- Can ARS Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 4.94 — current assets exceed current liabilities.
- Where does ARS Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from ARS Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
